Phibro Animal Health insider sales and Class B to A conversion
Rhea-AI Filing Summary
Phibro Animal Health (PAHC) insider activity: Reporting persons BFI Co., LLC and Jack Bendheim (Director, 10% Owner, President and CEO) reported sales and a conversion. Under a Rule 10b5‑1 plan, BFI sold 700 Class A shares on 10/17/2025 at a weighted average price of $40.0319 and 16,075 Class A shares on 10/20/2025 at a weighted average price of $40.3842.
On 10/21/2025, 50,000 shares of Class B Common Stock were converted into 50,000 shares of Class A on a one‑for‑one basis. Following these transactions, 73,899 Class A shares were indirectly beneficially owned, and 16,840 Class A shares were directly owned. After the conversion, 20,086,034 shares of Class B were indirectly beneficially owned.
Positive
- None.
Negative
- None.
Insights
Routine Form 4 showing planned sales and a Class B to A conversion.
BFI Co., LLC, over which Jack Bendheim has voting and dispositive power, sold 700 Class A shares at a weighted average of $40.0319 on 10/17/2025 and 16,075 Class A shares at a weighted average of $40.3842 on 10/20/2025 pursuant to a Rule 10b5‑1 plan adopted on May 30, 2025.
On 10/21/2025, 50,000 shares of Class B Common Stock were converted into 50,000 shares of Class A at a one‑for‑one rate; Class B has no expiration. Following the reported transactions, indirect holdings included 73,899 Class A shares and 20,086,034 Class B shares, and direct holdings included 16,840 Class A shares.
This filing lists transactions and resulting holdings; actual market impact depends on holder decisions and future disclosures.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 50,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 50,000 | $0.00 | -- |
| Sale | Class A Common Stock | 16,075 | $40.3842 | $649K |
| Sale | Class A Common Stock | 700 | $40.0319 | $28K |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.59. Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. The reported securities are directly held by Jack Bendheim.
